Artiva Biotherapeutics, Inc. (ARTV): EBITDA
-$87.21M
Year ended 2025-12-31
-$93.46M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$87.21M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$64.85M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | -$28.41M | n/a | 2025-03-24, From 2023-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | -$87.21M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $26.65M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $14.25B | +10.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $133.91M | +287.5% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $237.0K | -96.2% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $349.25M | +64.6% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$35.92M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $342.38M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $22.59M | +125.4% |
Compare ARTV, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗